You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag

Article info

Article menu
Download PDFPDF
Declarations of Interest
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag

Citation

S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag
Thorax 2016;71:A270.

Publication history

  • First published November 15, 2016.
Online issue publication 
September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions